Trevi Therapeutics Inc (NASDAQ:TRVI) reported a narrower-than-expected loss for the fourth quarter on Tuesday.

The company posted quarterly losses of 6 cents per share which beat the analyst consensus estimate of losses of 10 cents per share.

“Our progress in 2025 marked a major inflection point for Trevi’s growth trajectory, driven by positive Phase 2 data across our chronic cough programs,” said Jennifer Good, President and CEO of Trevi Therapeutics. “These results provide a strong foundation as we pursue our goal of becoming a leader in treating chronic cough. We’ve carried this momentum into 2026 as we gained overall alignment with the FDA during our End-of-Phase 2 meeting for patients with IPF-related chronic cough. We are now focused on initiating the first of our two pivotal Phase 3 IPF-related chronic cough trials, as well as our Phase 2b RCC trial in the second quarter of this year. Looking ahead, Trevi is well positioned to execute on its clinical programs and help address the high unmet need for patients who are burdened by chronic cough in our target indications, where there are no FDA-approved therapies.”

Trevi Therapeutics shares fell 2.5% to trade at $10.91 on Wednesday.

These analysts made changes to their price targets on Trevi Therapeutics following earnings announcement.

  • Needham analyst Serge Belanger maintained Trevi Therapeutics with a Buy and raised the price target from $22 to $24.
  • Morgan Stanley analyst Judah Frommer maintained the stock with an Overweight rating and lowered the price target from $19 to $18.

Considering buying TRVI stock? Here’s what analysts think:

Photo via Shutterstock